<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669068</url>
  </required_header>
  <id_info>
    <org_study_id>HRC-ENDOHEM-02</org_study_id>
    <nct_id>NCT03669068</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: THE ENDOHEM REGISTRY</brief_title>
  <official_title>Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: A Prospective, Multicentre, and Observational Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Central de Asturias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Viladecans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Avilés</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study evaluates the safety of gastrointestinal endoscopy in patients on
      oral anticoagulants (Vitamin K antagonists, rivaroxaban, dabigatran, edoxaban, and apixaban).
      This registry aims to assess the incidence, characteristics and risk factors for
      cardiovascular and bleeding events associated with an endoscopic procedure. Besides, it aims
      to evaluate the differences between Vitamin K antagonists and DOACs users and to estimate the
      impact of anticoagulation withdrawal time on the primary and secondary outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of Cardiovascular events</measure>
    <time_frame>3 months</time_frame>
    <description>Nº of patients during the study period presenting with a cardiovascular event, defined as any of the following entities: pulmonary thromboembolism, venous thromboembolism, acute coronary syndrome, arterial peripheral embolism or cerebrovascular accident.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of therapeutic endoscopy-related gastrointestinal bleeding</measure>
    <time_frame>3 months</time_frame>
    <description>Nº of patients during the study period presenting with therapeutic endoscopy-related gastrointestinal bleeding</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Gastrointestinal Bleeding</condition>
  <condition>Cardiovascular Complication</condition>
  <condition>Anticoagulants; Circulating, Hemorrhagic Disorder</condition>
  <condition>Gastrointestinal Endoscopy</condition>
  <arm_group>
    <arm_group_label>Elective endoscopy</arm_group_label>
    <description>Patients undergoing gastrointestinal endoscopy unrelated to anticoagulant-induced gastrointestinal bleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastrointestinal bleeding</arm_group_label>
    <description>Patients with anticoagulant-induced gastrointestinal bleeding will be analyzed separately</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrointestinal endoscopy</intervention_name>
    <description>Two separated groups will be included in the registry:
Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.
Patients undergoing elective gastrointestinal endoscopy.</description>
    <arm_group_label>Elective endoscopy</arm_group_label>
    <arm_group_label>Gastrointestinal bleeding</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients on oral anticoagulants (Vitamin K antagonist, apixaban, edoxaban, rivaroxaban or
        dabigatran)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years.

          -  Patients with preoperative use of oral anticoagulants (Vitamin K antagonist, apixaban,
             edoxaban, rivaroxaban or dabigatrán) undergoing gastrointestinal endoscopy.

          -  Patients on oral anticoagulants (Vitamin K antagonist, apixaban, edoxaban, rivaroxaban
             or dabigatran) presenting with gastrointestinal bleeding, regardless of receiving
             gastrointestinal endoscopy.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Negative to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enrique Rodríguez de Santiago, M.D</last_name>
    <phone>+0034651913608</phone>
    <email>e_rodriguez_de_santiago@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agustín Albillos Martínez, M.D PhD</last_name>
    <phone>913368592</phone>
    <email>agustin.albillos@uah.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustin Albillos Martinez, MD PHD</last_name>
      <phone>91 3368592</phone>
      <email>agustin.albillos@uah.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 8, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Enrique Rodríguez de Santiago</investigator_full_name>
    <investigator_title>Principal Investigator. MSc. Gastroenterologist</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal endoscopy</keyword>
  <keyword>Oral anticoagulants</keyword>
  <keyword>Gastrointestinal bleeding</keyword>
  <keyword>Cardiovascular event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Available. Timeframe: 2018-2021</ipd_time_frame>
    <ipd_access_criteria>Accredited researchers. The protocol is available in Spanish and will be provided by contacting the principal investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

